A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
A phase 3 trial testing Setidegrasib in non-small-cell lung cancer, now recruiting.
Overview
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation is a phase 3 interventional study registered as NCT07566052, led by Astellas Pharma Global Development, and recruiting when checked on 2026-09-11. Official title: A Randomised, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI). Planned enrolment is 356 participants (estimated). The study started in 2026-04-28 and primary completion is expected in 2030-06-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Shares Setidegrasib, Astellas and the tag ctgov-ingest.
- TrialA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Shares Astellas and the tag ctgov-ingest.
- TrialSSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.